Published in Haematologica on September 22, 2009
Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant (2011) 1.46
Quantitative tracking of T cell clones after haematopoietic stem cell transplantation. EMBO Mol Med (2011) 1.29
Immunological applications of stem cells in type 1 diabetes. Endocr Rev (2011) 1.20
Therapy with stem cells in inflammatory bowel disease. World J Gastroenterol (2014) 1.03
Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies. Biol Blood Marrow Transplant (2010) 1.02
Dysphagia as a risk factor for mortality in Niemann-Pick disease type C: systematic literature review and evidence from studies with miglustat. Orphanet J Rare Dis (2012) 0.99
Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus. Ann Rheum Dis (2011) 0.96
Cell Therapy From Bench to Bedside Translation in CNS Neurorestoratology Era. Cell Med (2010) 0.96
Transplantation for autoimmune diseases in north and South America: a report of the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant (2012) 0.94
New and emerging treatment approaches to lupus. Biologics (2010) 0.92
Hematopoietic stem cell therapy for multiple sclerosis: top 10 lessons learned. Neurotherapeutics (2013) 0.91
High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases. Medicine (Baltimore) (2011) 0.91
Non-embryo-destructive Extraction of Pluripotent Embryonic Stem Cells: Implications for Regenerative Medicine and Reproductive Medicine. Geburtshilfe Frauenheilkd (2015) 0.90
Diabetic ketoacidosis at diagnosis influences complete remission after treatment with hematopoietic stem cell transplantation in adolescents with type 1 diabetes. Diabetes Care (2012) 0.89
Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives. Drugs (2016) 0.88
Clinical and histopathological features of patients with systemic sclerosis undergoing endomyocardial biopsy. PLoS One (2015) 0.83
Stem cell transplantation for autoimmune diseases. Haematologica (2010) 0.83
Impact of passing mesenchymal stem cells through smaller bore size needles for subsequent use in patients for clinical or cosmetic indications. J Transl Med (2012) 0.83
Haematopoietic stem cell transplantation for autoimmune diseases. Nat Rev Rheumatol (2017) 0.81
Does ex vivo CD34+ positive selection influence outcome after autologous hematopoietic stem cell transplantation in systemic sclerosis patients? Bone Marrow Transplant (2015) 0.81
Autologous hematopoietic SCT normalizes miR-16, -155 and -142-3p expression in multiple sclerosis patients. Bone Marrow Transplant (2014) 0.81
SCT for severe autoimmune diseases: consensus guidelines of the European Society for Blood and Marrow Transplantation for immune monitoring and biobanking. Bone Marrow Transplant (2014) 0.81
Stem cells: HSCT for Crohn's disease: work in progress or a bridge too far? Nat Rev Gastroenterol Hepatol (2016) 0.79
Hematopoietic stem cell transplantation for systemic lupus erythematosus. Clin Dev Immunol (2012) 0.79
Anti-CD52 antibody-mediated immune ablation with autologous immune recovery for the treatment of refractory juvenile polymyositis. J Clin Immunol (2011) 0.78
High-dose cyclophosphamide without stem cell rescue for the treatment of refractory Behcet's disease. Semin Arthritis Rheum (2011) 0.78
High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS. Neurology (2017) 0.77
Stem cells: HSCT for systemic sclerosis--swallows and summers. Nat Rev Rheumatol (2011) 0.77
Remitting-relapsing multiple sclerosis patient refractory to conventional treatments and bone marrow transplantation who responded to natalizumab. Int J Gen Med (2010) 0.77
Stem cell treatment for type 1 diabetes. Front Cell Dev Biol (2014) 0.77
Mechanisms determining the fate of hematopoietic stem cells. Stem Cell Investig (2015) 0.76
Autologous hematopoietic stem cell transplantation in multiple sclerosis: 20 years of experience. Neurol Sci (2016) 0.76
Immunoablation and Stem Cell Transplantation in Amyotrophic Lateral Sclerosis: The Ultimate Test for the Autoimmune Pathogenesis Hypothesis. Front Neurol (2016) 0.76
Functional autoantibodies in systemic sclerosis. Semin Immunopathol (2015) 0.76
Guidelines of the Brazilian society of bone Marrow transplantation on hematopoietic stem cell transplantation as a treatment for the autoimmune diseases systemic sclerosis and multiple sclerosis. Rev Bras Hematol Hemoter (2013) 0.75
Hematopoietic stem cell transplantation for multiple sclerosis: is it a clinical reality? Stem Cell Res Ther (2016) 0.75
Effect of stem cell transplantation for B-cell malignancies on disease course of associated polyneuropathy. J Neurol (2012) 0.75
Stem cell-based therapies in inflammatory bowel disease: promises and pitfalls. Therap Adv Gastroenterol (2016) 0.75
Treatment of refractory ITP and Evans syndrome by haematopoietic cell transplantation: is it indicated, and for whom? Vox Sang (2015) 0.75
Pulmonary Arterial Hypertension-A Deadly Complication of Systemic Sclerosis. J Clin Rheumatol Musculoskelet Med (2010) 0.75
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis. Nat Rev Neurol (2017) 0.75
Repeated treatment with high dose cyclophosphamide for severe autoimmune diseases. Am J Blood Res (2013) 0.75
Immune-regulatory mechanisms in systemic autoimmune and rheumatic diseases. Clin Dev Immunol (2011) 0.75
Hematopoietic stem cell transplantation for auto immune rheumatic diseases. World J Transplant (2016) 0.75
Immunological Balance Is Associated with Clinical Outcome after Autologous Hematopoietic Stem Cell Transplantation in Type 1 Diabetes. Front Immunol (2017) 0.75
Immunomodulation Induced by Stem Cell Mobilization and Harvesting in Healthy Donors: Increased Systemic Osteopontin Levels after Treatment with Granulocyte Colony-Stimulating Factor. Int J Mol Sci (2016) 0.75
Review: Hematopoietic Stem Cell Transplantation for Scleroderma: Effective Immunomodulatory Therapy for Patients With Pulmonary Involvement. Arthritis Rheumatol (2016) 0.75
Lymphocyte reconstitution following autologous stem cell transplantation for progressive MS. Mult Scler J Exp Transl Clin (2017) 0.75
Autologous hematopoietic cell transplantation for systemic sclerosis - a challenge for the Canadian health care system. CMAJ (2017) 0.75
Stem cell autograft and allograft in autoimmune diseases. Clin Exp Med (2014) 0.75
Long-term follow-up of fertility and pregnancy in autoimmune diseases after autologous haematopoietic stem cell transplantation. Rheumatol Int (2016) 0.75
Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med (1999) 22.81
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet (2007) 20.57
Autoimmune diseases. N Engl J Med (2001) 3.60
Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol (2009) 2.48
A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis. Arthritis Rheum (2002) 2.44
Autologous haemopoietic stem-cell transplantation in four patients with refractory juvenile chronic arthritis. Lancet (1999) 2.39
Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA (2006) 2.34
Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med (2005) 2.30
Treatment of systemic sclerosis with autologous haemopoietic stem cell transplantation. Lancet (1997) 1.76
Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) (2002) 1.72
Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult Scler (2006) 1.70
Treatment of severe autoimmune disease by stem-cell transplantation. Nature (2005) 1.45
Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol (2008) 1.43
Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplant (2005) 1.37
Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis (2004) 1.30
Autologous stem cell transplantation for systemic lupus erythematosus. Lupus (2004) 1.24
Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med (2006) 1.24
Long-term observations of autoimmune-prone mice treated for autoimmune disease by allogeneic bone marrow transplantation. Proc Natl Acad Sci U S A (1989) 1.21
Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther (2008) 1.08
Analysis of immune reconstitution after autologous bone marrow transplantation in systemic sclerosis. Arthritis Rheum (2005) 1.05
Haemopoietic stem and progenitor cells in the treatment of severe autoimmune diseases. Ann Rheum Dis (1996) 1.05
Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: twelve-year outcomes. Arthritis Rheum (2008) 1.01
Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis. Bone Marrow Transplant (2004) 1.01
Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Ann Rheum Dis (2007) 1.01
Stem cell transplantation for autoimmune disorders. Preclinical experiments. Best Pract Res Clin Haematol (2004) 0.92
Stem cell transplantation for inflammatory bowel disease: practical and ethical issues. Gut (2000) 0.88
Haemopoietic stem cell transplantation in autoimmune diseases: a European perspective. Br J Haematol (2005) 0.88
Haematopoetic stem cell transplantation for refractory autoimmune cytopenia. Br J Haematol (2004) 0.86
Hematopoietic stem cell transplantation for systemic lupus erythematosus, the antiphospholipid syndrome and bullous skin diseases. Autoimmunity (2008) 0.85
High-dose cyclophosphamide and stem cell transplantation for refractory systemic lupus erythematosus. JAMA (2006) 0.84
Cell therapy for autoimmune diseases: does it have a future? Ann Rheum Dis (2004) 0.83
Autologous stem cell transplantation for systemic sclerosis. Autoimmunity (2008) 0.79
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med (2006) 22.86
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med (2003) 17.23
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol (2009) 9.40
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med (2002) 8.86
Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med (2006) 7.89
Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med (2004) 7.73
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood (2006) 6.89
American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum (2011) 6.28
Youth risk behavior surveillance--United States, 2013. MMWR Surveill Summ (2014) 6.17
2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum (2013) 5.99
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood (2002) 5.47
Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med (2003) 4.90
High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med (2009) 4.90
hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res (2008) 4.84
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol (2010) 4.79
American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis (2011) 4.15
Cytarabine dose for acute myeloid leukemia. N Engl J Med (2011) 4.15
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood (2002) 4.00
Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol (2009) 3.89
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood (2002) 3.60
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis (2013) 3.11
Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia. J Clin Oncol (2011) 3.09
Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. Blood (2006) 2.77
Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis (2010) 2.71
Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol (2008) 2.70
Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood (2007) 2.61
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood (2002) 2.33
Human leukocyte antigen DR15 is associated with reduced relapse rate and improved survival after human leukocyte antigen-identical sibling hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2006) 2.29
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood (2012) 2.21
Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol (2009) 2.18
Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. Lancet Infect Dis (2013) 2.17
Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol (2005) 2.15
Adverse event rates in congenital cardiac catheterization - a multi-center experience. Catheter Cardiovasc Interv (2010) 2.15
Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res (2002) 2.13
Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID). J Rheumatol (2012) 2.12
KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transplant (2006) 2.10
Bronchoscopic guidance of endovascular stenting limits airway compression. Catheter Cardiovasc Interv (2014) 2.07
The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol (2012) 2.05
Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood (2002) 2.03
Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol (2009) 1.98
The importance of HLA-DPB1 in unrelated donor hematopoietic cell transplantation. Blood (2007) 1.96
A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions. J Clin Epidemiol (2013) 1.92
Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party. Blood (2011) 1.89
Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet's disease. Arthritis Rheum (2010) 1.84
The SUMO-specific protease SENP5 is required for cell division. Mol Cell Biol (2006) 1.81
Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute-Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005. Biol Blood Marrow Transplant (2005) 1.81
The Arabidopsis E3 SUMO ligase SIZ1 regulates plant growth and drought responses. Plant Cell (2007) 1.79
Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature. Clin Infect Dis (2008) 1.79
Predicting outcome after lung resection for invasive pulmonary aspergillosis in patients with neutropenia. Chest (2004) 1.78
Prediction of hip fracture risk by quantitative ultrasound in more than 7000 Swiss women > or =70 years of age: comparison of three technologically different bone ultrasound devices in the SEMOF study. J Bone Miner Res (2006) 1.78
The use of nonhuman primate models in HIV vaccine development. PLoS Med (2008) 1.73
Severe events in donors after allogeneic hematopoietic stem cell donation. Haematologica (2008) 1.72
Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood (2006) 1.71
Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood (2005) 1.71
Immunoglobulin genes in multiple myeloma: expressed and non-expressed repertoires, heavy and light chain pairings and somatic mutation patterns in a series of 101 cases. Haematologica (2006) 1.67
Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood (2007) 1.67
Autologous mesenchymal stem cells foster revascularization of ischemic limbs in systemic sclerosis: a case report. Ann Intern Med (2010) 1.65
Higher incidence of relapse with peripheral blood rather than marrow as a source of stem cells in adults with acute myelocytic leukemia autografted during the first remission. J Clin Oncol (2009) 1.64
Impact of HLA-DPB1 haplotypes on outcome of 10/10 matched unrelated hematopoietic stem cell donor transplants depends on MHC-linked microsatellite polymorphisms. Biol Blood Marrow Transplant (2011) 1.63
Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative to lymphoablative transplant regimens. Arthritis Rheum (2006) 1.62
Summary of the National Toxicology Program's report of the endocrine disruptors low-dose peer review. Environ Health Perspect (2002) 1.60
Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J Clin Oncol (2012) 1.60
Safety of percutaneous patent ductus arteriosus closure: an unselected multicenter population experience. J Am Heart Assoc (2013) 1.59
The gene Sr33, an ortholog of barley Mla genes, encodes resistance to wheat stem rust race Ug99. Science (2013) 1.55
A SIRT1-LSD1 corepressor complex regulates Notch target gene expression and development. Mol Cell (2011) 1.55
Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol (2002) 1.54
Dendritic cells in multiple sclerosis lesions: maturation stage, myelin uptake, and interaction with proliferating T cells. J Neuropathol Exp Neurol (2006) 1.52
A comprehensive study of TP53 mutations in chronic lymphocytic leukemia: Analysis of 1287 diagnostic and 1148 follow-up CLL samples. Leuk Res (2011) 1.52
Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma. Leuk Lymphoma (2011) 1.50
Validation of the EBMT risk score in chronic myeloid leukemia in Brazil and allogeneic transplant outcome. Haematologica (2005) 1.50
Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood (2011) 1.50
Association of TNFd and IL-10 polymorphisms with mortality in unrelated hematopoietic stem cell transplantation. Transplantation (2006) 1.49
Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet (2002) 1.49
The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease. Eur J Nucl Med Mol Imaging (2005) 1.47
Candidatus Neoehrlichia mikurensis infection identified in 2 hematooncologic patients: benefit of molecular techniques for rare pathogen detection. Diagn Microbiol Infect Dis (2011) 1.45
The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders. Haematologica (2008) 1.45